Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Breast Cancer | Research

Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions

Authors: Huayong Jiang, Lingling Meng, Huijuan Zhang, Xiangkun Dai, Qian Zhang, Zhongjian Ju, Wei Yu, Lin Ma

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

The purpose of this phase II study was to evaluate the feasibility of hypofractionated radiotherapy (HFRT) with a dose of 36.5 Gy in 10 fractions in postmastectomy patients.

Methods

From March 2014 to December 2015, 85 patients with locally advanced breast cancer were eligible to participate in this study with a schedule of 36.5 Gy in 10 fractions. Intensity-modulated radiation therapy (IMRT) was delivered to the chest wall with or without the supraclavicular region. The primary endpoint was radiation-related toxicities. The secondary endpoints were locoregional failure-free survival (LRFFS), disease-free survival (DFS) and overall survival (OS). And the outcomes were compared with our retrospective study of 72 patients with 42.5 Gy in 16 fractions.

Results

The median follow-up was 69.0 (range 66.5-71.5) months in the 36.5 Gy group and 93.0 (range 91.9-94.1) months in the 42.5 Gy group, respectively. Radiation-related toxicities were mainly grade 1, although a few patients had grade 2 plexopathy (1.2%) and acute skin toxicity (1.2%) in the 36.5 Gy group, and grade 2 acute skin toxicity (5.6%) and lymphedema (4.2%) in the 42.5 Gy group. There were no significant differences between the groups in acute and late toxicities. For all the patients, the 5-year LRFFS, DFS and OS were 97.7 and 100.0%, 93.1 and 90.3%, 98.8 and 97.2%, respectively, without significant differences between the groups.

Conclusion

Postmastectomy HFRT with a schedule of 36.5 Gy in 10 fractions was feasible, with mild toxicities and excellent 5-year clinical outcome.

Trial registration

Trial registration number: ChiCTR-ONRC-14004391.

Date of registration: 9/3/2014.

International Agency for Research on Cancer (IARC). Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020. Available from: https://www.iarc.who.int/fr/news-events. Accessed 25 Feb 2021.

Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106. https://doi.org/10.1016/S0140-6736(05)67887-7.CrossRefPubMed

Nielsen HM, Overgaard M, Grau C, et al. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish breast cancer cooperative group DBCG 82 b and c randomized studies. J Clin Oncol. 2006;24:2268–75. https://doi.org/10.1200/JCO.2005.02.8738.CrossRefPubMed

Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35. https://doi.org/10.1016/S0140-6736(14)60488-8.CrossRef

Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20. https://doi.org/10.1056/NEJMoa0906260.CrossRefPubMed

Offersen BV, Alsner J, Nielsen HM, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial. J Clin Oncol. 2020;38:3615–25. https://doi.org/10.1200/JCO.20.01363.CrossRefPubMed

Haviland JS, Owen JR, Dewar JA, et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–94. https://doi.org/10.1016/S1470-2045(13)70386-3.CrossRefPubMed

Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019;20:352–60. https://doi.org/10.1016/S1470-2045(18)30813-1.CrossRefPubMed

Khan AJ, Poppe MM, Goyal S, et al. Hypofractionated postmastectomy radiation therapy is safe and effective: first results from a prospective phase II trial. J Clin Oncol. 2017;35:2037–43. https://doi.org/10.1200/JCO.2016.70.7158.CrossRefPubMedPubMedCentral

10.

Baillet F, Housset M, Maylin C, et al. The use of a specific hypofractionated radiation therapy regimen versus classical fractionation in the treatment of breast cancer: a randomized study of 230 patients. Int J Radiat Oncol Biol Phys. 1990;19:1131–3. https://doi.org/10.1016/0360-3016(90)90216-7.CrossRefPubMed

11.

Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395:1613–26. https://doi.org/10.5271/sjweh.3960.CrossRefPubMedPubMedCentral

12.

Rosenstein BS, Lymberis SC, Formenti SC. Biologic comparison of partial breast irradiation protocols. Int J Radiat Oncol Biol Phys. 2004;60:1393–404. https://doi.org/10.1016/j.ijrobp.2004.05.072.CrossRefPubMed

13.

Thames HD, Bentzen SM, Turesson I, et al. Time-dose factors in radiotherapy: a review of the human data. Radiother Oncol. 1990;19:219–35. https://doi.org/10.1016/0167-8140(90)90149-q.CrossRefPubMed

14.

Dale RG. Time-dependent tumour repopulation factors in linear-quadratic equations--implications for treatment strategies. Radiother Oncol. 1989;15:371–81. https://doi.org/10.1016/0167-8140(89)90084-4.CrossRefPubMed

15.

Poppe MM, Yehia ZA, Baker C, et al. 5-year update of a multi-institution prospective phase 2 hypofractionated postmastectomy radiation therapy trial. Int J Radiat Oncol Biol Phys. 2020;107:694–700. https://doi.org/10.1016/j.ijrobp.2020.03.020.CrossRefPubMedPubMedCentral

16.

Kouloulias V, Mosa E, Zygogianni A, et al. A retrospective analysis of toxicity and efficacy for 2 hypofractionated irradiation schedules versus a conventional one for post-mastectomy adjuvant radiotherapy in breast cancer. Breast Care. 2016;11:328–32. https://doi.org/10.1159/000449433.CrossRefPubMedPubMedCentral

17.

Chitapanarux I, Klunklin P, Pinitpatcharalert A, et al. Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity. Radiat Oncol. 2019;14:175–84. https://doi.org/10.1186/s13014-019-1378-x.CrossRefPubMedPubMedCentral

18.

Koulis TA, Nichol AM, Truong PT, et al. Hypofractionated adjuvant radiation therapy is effective for patients with lymph node-positive breast cancer: a population-based analysis. Int J Radiat Oncol Biol Phys. 2020;108:1150–8. https://doi.org/10.1016/j.ijrobp.2020.07.2313.CrossRefPubMed

19.

Radiation Therapy Oncology Group (RTOG). Breast cancer atlas for radiation therapy planning: consensus definitions. Available from: http://www.rtog.org/LinkClick.aspx?fileticket=vzJFhPaBipE%3d&tabid=236. Accessed 10 Apr 2021.

20.

Offersen BV, Boersma LJ, Kirkove C, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol. 2015;114:3–10. https://doi.org/10.1016/j.radonc.2014.11.030.CrossRefPubMed

21.

Chang JS, Lee J, Chun M, et al. Mapping patterns of locoregional recurrence following contemporary treatment with radiation therapy for breast cancer: a multi-institutional validation study of the ESTRO consensus guideline on clinical target volume. Radiother Oncol. 2018;126:139–47. https://doi.org/10.1016/j.radonc.2017.09.031.CrossRefPubMed

22.

Wang EH, Mougalian SS, Soulos PR, et al. Adoption of intensity modulated radiation therapy for early-stage breast cancer from 2004 through 2011. Int J Radiat Oncol Biol Phys. 2015;91:303–11. https://doi.org/10.1016/j.ijrobp.2014.09.011.CrossRefPubMed

23.

Donovan E, Bleakley N, Denholm E, Breast Technology Group. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol. 2007;82:254–64. https://doi.org/10.1016/j.radonc.2006.12.008.CrossRefPubMed

24.

Rastogi K, Sharma S, Gupta S, et al. Dosimetric comparison of IMRT versus 3DCRT for post-mastectomy chest wall irradiation. Radiat Oncol J. 2018;36:71–8. https://doi.org/10.3857/roj.2017.00381.CrossRefPubMedPubMedCentral

25.

Jagsi R, Griffith KA, Moran JM, et al. A randomized comparison of radiation therapy techniques in the Management of Node-Positive Breast Cancer: primary outcomes analysis. Int J Radiat Oncol Biol Phys. 2018;101:1149–58. https://doi.org/10.1016/j.ijrobp.2018.04.075.CrossRefPubMedPubMedCentral

26.

Bazan JG, Healy E, Beyer S, et al. Clinical effectiveness of an adaptive treatment planning algorithm for intensity modulated radiation therapy versus 3D conformal radiation therapy for node-positive breast cancer patients undergoing regional nodal irradiation/Postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 2020;108:1159–71. https://doi.org/10.1016/j.ijrobp.2020.07.027.CrossRefPubMed

27.

Pignol J-P, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008;26:2085–92. https://doi.org/10.1200/JCO.2007.15.2488.CrossRefPubMed

28.

Li J, Wang X, Ma J, et al. Prospective evaluation of skin toxicities in patients receiving post-mastectomy irradiation of chest wall, supra/infraclavicular and internal mammary nodes delivered by conventional versus intensity-modulated radiotherapy technique. Oncotarget. 2017;8:80012–9. https://doi.org/10.18632/oncotarget.20820.CrossRefPubMedPubMedCentral

29.

Lancellotta V, Iacco M, Perrucci E, et al. Comparing four radiotherapy techniques for treating the chest wall plus levels III-IV draining nodes after breast reconstruction. Br J Radiol. 2018;91(1086):20160874. https://doi.org/10.1259/bjr.20160874.CrossRefPubMedPubMedCentral

30.

Lancellotta V, Chierchini S, Perrucci E, et al. Skin toxicity after chest wall/breast plus level III-IV lymph nodes treatment with helical tomotherapy. Cancer Investig. 2018;36:504–11. https://doi.org/10.1080/07357907.2018.1545854.CrossRef

Title: Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions
Authors: Huayong Jiang
Lingling Meng
Huijuan Zhang
Xiangkun Dai
Qian Zhang
Zhongjian Ju
Wei Yu
Lin Ma
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Radiotherapy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-09032-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2021

Comparing the 7th and 8th editions of UICC/AJCC staging system for nasopharyngeal carcinoma in the IMRT era

Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs

Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study

Prognostic role of preoperative D-dimer, fibrinogen and platelet levels in patients with oral squamous cell carcinoma

Albumin-to-alkaline phosphatase ratio as a promising indicator of prognosis in human cancers: is it possible?

Alternative splicing associated with cancer stemness in kidney renal clear cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer